The 76-week trial met its co-primary endpoints, with up to 13.1% average weight loss using the efficacy estimand and improvements in HbA1c, waist circumference and insulin sensitivity. IN BRIEFKEY TAKEAWAYSFAQs Boehringer Ingelheim reported positive Phase III SYNCHRONIZE-2 results for investigational … Read the full press release
Posted in Germany, Healthcare, Pharma & Biotech
Tagged BI 456906, Boehringer Ingelheim, Boehringer Ingelheim presents survodutide Phase III results in obesity or overweight with type 2 diabetes, Boehringer Ingelheim’s SYNCHRONIZE-2 trial reports up to 13.1% average weight loss with investigational survodutide in adults with type 2 diabetes, cardiometabolic health, Dual Agonist, EASD, European Association for the Study of Diabetes, Germany, GLP-1, glucagon receptor, glycemic control, HbA1c, Ingelheim, insulin sensitivity, LIVERAGE, LIVERAGE-Cirrhosis, MASH, Obesity, overweight, Phase III SYNCHRONIZE-2 data show survodutide met co-primary weight-loss endpoints and improved glycemic markers, Sean Wharton, Shashank Deshpande, Survodutide, SYNCHRONIZE-1, SYNCHRONIZE-2, SYNCHRONIZE-2 findings show weight reduction alongside HbA1c and insulin-sensitivity improvements with survodutide, SYNCHRONIZE-CVOT, SYNCHRONIZE-T2D, T2D, The New England Journal of Medicine, type 2 diabetes, Zealand Pharma
(IN BRIEF) Boehringer Ingelheim has received European Commission marketing authorisation for JASCAYD® (nerandomilast) for adults with idiopathic pulmonary fibrosis and progressive pulmonary fibrosis. JASCAYD is the first oral preferential PDE4B inhibitor approved in the EU, offering a new mechanism of … Read the full press release
Posted in Business, European Union, Germany, Healthcare, Pharma & Biotech, Science, Technology
Tagged antifibrotic effects, Boehringer Ingelheim, CHMP, clinical trials, Erasmus MC University Medical Centre, European Approval of JASCAYD Brings New Oral Treatment Option for Progressive Lung Fibrosis, European Commission, European Union approval, Federation of European Scleroderma Associations, FESCA, FIBRONEER, FIBRONEER Trial Data Support EU Authorisation of Nerandomilast for IPF and PPF, FIBRONEER-ILD, FIBRONEER-IPF, forced vital capacity, FVC, idiopathic pulmonary fibrosis, immunomodulatory effects, IPF, JASCAYD, JASCAYD Becomes First Oral Preferential PDE4B Inhibitor Approved in the EU for IPF and PPF, lung function decline, lung scarring, Marketing Authorisation, Marlies Wijsenbeek, myositis, nerandomilast, PDE4B inhibitor, phosphodiesterase 4B, PPF, progressive lung disease, progressive pulmonary fibrosis, pulmonary fibrosis, rare lung disease, respiratory disease, rheumatic diseases, Shashank Deshpande, Sue Farrington, systemic sclerosis
(IN BRIEF) Boehringer Ingelheim has received approval from Japan’s Ministry of Health, Labour and Welfare for JASCAYD® (nerandomilast) to treat adults with idiopathic pulmonary fibrosis and progressive pulmonary fibrosis. The oral PDE4B inhibitor is the first therapy of its kind … Read the full press release
Posted in Business, Financial, Germany, Government, Healthcare, Industrial, Investment, Management, Marketing, Pharma & Biotech, Science, Security & Safety, Technology
Tagged antifibrotic treatment, Arata Azuma, Boehringer Ingelheim, clinical trials, FIBRONEER, fibrosis treatment, forced vital capacity, idiopathic pulmonary fibrosis, immunomodulatory therapy, IPF, Japan Ministry of Health Labour and Welfare, JASCAYD, lung disease, lung function decline, MHLW, nerandomilast, PDE4B inhibitor, pharmaceutical industry, PPF, progressive pulmonary fibrosis, pulmonary fibrosis, rare diseases, respiratory health, respiratory medicine, Shashank Deshpande
(IN BRIEF) Boehringer Ingelheim’s HERNEXEOS® (zongertinib tablets) has received accelerated approval in China for patients with advanced NSCLC carrying HER2 mutations who have progressed after prior therapy. The approval is supported by Beamion-LUNG 1 data, which showed a 71% objective … Read the full press release
Posted in Business, Financial, Germany, Healthcare, Industrial, Investment, Management, Marketing, News, Pharma & Biotech, Science, Security & Safety, Technology
Tagged AACR 2025, Beamion-LUNG 1, Beamion-LUNG 2, Boehringer Ingelheim, breakthrough therapy designation, CHINA, HER2 mutations, HERNEXEOS, New England Journal of Medicine, NMPA approval, non-small cell lung cancer, NSCLC, oncology, partnership, Shashank Deshpande, targeted therapy, tyrosine kinase inhibitor, Wu Yilong, zongertinib
(IN BRIEF) Boehringer Ingelheim and LEO Pharma have agreed on a global license and transfer deal for SPEVIGO® (spesolimab), an antibody that blocks the IL‑36 receptor to treat generalized pustular psoriasis (GPP). LEO Pharma will assume worldwide commercialization and clinical development, harnessing … Read the full press release
Posted in Business, Denmark, Financial, Germany, Government, Healthcare, Industrial, Investment, Management, Marketing, News, Pharma & Biotech, Science, Technology
Tagged Boehringer Ingelheim, Christophe Bourdon, clinical development, commercialization, Dermatology, EUR 90 million, generalized pustular psoriasis, global license, GPP, IL‑36 receptor, LEO Pharma, monoclonal antibody, partnership, rare skin disease, Shashank Deshpande, spesolimab, SPEVIGO
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions. Here you can learn more about EuropaWire’s mission, achievements, services, etc.
HOW TO GET STARTED?